Justin J. Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Justin J. Kim has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Christopher Alexander French
Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
12 shared publications - Geoffrey I. Shapiro
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
12 shared publications - Glenn J. Hanna
Dana-Farber Cancer Institute 1 Department of Medical Oncology Boston, Massachusetts
12 shared publications - Jamie E. Chaft
Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
12 shared publications - Jia Luo
Dana–Farber Cancer Institute, Boston
12 shared publications - Lynette M. Sholl
Department of Pathology, Brigham and Women’s Hospital, Boston, USA
12 shared publications
Latest Publications
- 9 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- p. OF1-OF25
Dual Functions of B7-H3–MAPK Signaling Orchestrate Tumor Immunosuppression via Regulating the Plasticity of Myeloid-Derived Suppressor Cells and Fibroblasts
B7-H3/CD276 is an emerging immunotherapy target in cancers. However, limited knowledge of B7-H3 signaling and its role in modulating the tumor microenvironment hinders the clinical application of B7-H3–targeting therapy. In this study, we report that B7-H3 plays dual roles in regulating myeloid-derived suppressor cells (MDSC) and cancer-associated fibroblasts (CAF), thereby promoting tumor progression and therapy resistance, respectively. We comprehensively characterized a noncanonical function of B7-H3 that triggers MAPK signaling in monocytic MDSCs (M-MDSC) and induces cellular senescence. The senescent M-MDSCs secreted chemokines to recruit immunosuppressive granulocytic MDSCs (Gr-MDSC). Genetic deletion or pharmacologic inhibition of B7-H3/CD276 reduced Gr-MDSCs and delayed tumor progression. Nevertheless, the secretory factor SPINK1 derived from MDSCs compensatorily activates EGFR/MEK/ERK signaling in CAFs and promotes their extracellular matrix remodeling features, dampening B7-H3–targeting immunotherapy. Combining the B7-H3 monoclonal antibody with the FDA-approved MEK inhibitor trametinib showed durable antitumor effects in preclinical models of castration-resistant prostate cancer by fully attenuating immunosuppressive mechanisms. Significance: Our studies uncovered a long-unknown B7-H3 signaling that orchestrates the cross-talk of cancer cells with myeloid and stromal cells in the host and provided novel mechanistic insights and effective combinatorial strategies for B7-H3–targeting immunotherapy in advanced prostate cancer among other malignancies.
- 9 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- p. OF1-OF25
Dual Functions of B7-H3–MAPK Signaling Orchestrate Tumor Immunosuppression via Regulating the Plasticity of Myeloid-Derived Suppressor Cells and Fibroblasts
B7-H3/CD276 is an emerging immunotherapy target in cancers. However, limited knowledge of B7-H3 signaling and its role in modulating the tumor microenvironment hinders the clinical application of B7-H3–targeting therapy. In this study, we report that B7-H3 plays dual roles in regulating myeloid-derived suppressor cells (MDSC) and cancer-associated fibroblasts (CAF), thereby promoting tumor progression and therapy resistance, respectively. We comprehensively characterized a noncanonical function of B7-H3 that triggers MAPK signaling in monocytic MDSCs (M-MDSC) and induces cellular senescence. The senescent M-MDSCs secreted chemokines to recruit immunosuppressive granulocytic MDSCs (Gr-MDSC). Genetic deletion or pharmacologic inhibition of B7-H3/CD276 reduced Gr-MDSCs and delayed tumor progression. Nevertheless, the secretory factor SPINK1 derived from MDSCs compensatorily activates EGFR/MEK/ERK signaling in CAFs and promotes their extracellular matrix remodeling features, dampening B7-H3–targeting immunotherapy. Combining the B7-H3 monoclonal antibody with the FDA-approved MEK inhibitor trametinib showed durable antitumor effects in preclinical models of castration-resistant prostate cancer by fully attenuating immunosuppressive mechanisms. Significance: Our studies uncovered a long-unknown B7-H3 signaling that orchestrates the cross-talk of cancer cells with myeloid and stromal cells in the host and provided novel mechanistic insights and effective combinatorial strategies for B7-H3–targeting immunotherapy in advanced prostate cancer among other malignancies.
- 1 December 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2500526
Presenting Features and Causes of Diagnostic Delays: A Report From the NUT Carcinoma Registry
PURPOSE: Diagnostic delays are common for patients with NUT carcinoma (NC), a cancer driven by NUT fusion oncoprotein. Rapid diagnosis is crucial for the best outcomes. We investigated NC's presenting features and associations with diagnostic delays. METHODS: We manually reviewed medical records from US participants in the NC Registry (2007-2024). Baseline features were analyzed descriptively, and multivariable logistic regression was used to examine odds ratios for delays. RESULTS: We analyzed 132 patients (median age 37 years). At presentation, 55% had metastatic disease and 64% had a thoracic primary. The median interval from symptom onset to diagnosis was 10 weeks (range, 1-165 weeks). The initial histopathologic diagnosis was poorly differentiated/squamous cell cancer in 52%, insufficient malignant cells in 14%, carcinoma in 12%, and NC in 22%. Immunohistochemistry (IHC) testing revealed NUT in 100%; 93% were keratin+, 88% p63+, 89% p40+, and 72% had Ki-67 ≥50%. IHC was used to diagnose NC in 79%. Nonthoracic primaries were associated with a longer time between symptom onset and NC diagnosis (odds ratio, 3.25). Of 32 patients who started treatment before diagnosis, 78% were on agents appropriate for NC. After a diagnosis of NC, 33% participated in clinical trials. CONCLUSION: NC almost always presents as squamous/poorly differentiated non–small cell lung or head and neck cancer. Overall, 78% of patients were initially diagnosed as non-NC. Efforts to raise awareness, recognition, and rapid diagnosis of NC by both oncologists and pathologists are critical if we are to improve outcomes.
- 1 December 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2500526
Presenting Features and Causes of Diagnostic Delays: A Report From the NUT Carcinoma Registry
PURPOSE: Diagnostic delays are common for patients with NUT carcinoma (NC), a cancer driven by NUT fusion oncoprotein. Rapid diagnosis is crucial for the best outcomes. We investigated NC's presenting features and associations with diagnostic delays. METHODS: We manually reviewed medical records from US participants in the NC Registry (2007-2024). Baseline features were analyzed descriptively, and multivariable logistic regression was used to examine odds ratios for delays. RESULTS: We analyzed 132 patients (median age 37 years). At presentation, 55% had metastatic disease and 64% had a thoracic primary. The median interval from symptom onset to diagnosis was 10 weeks (range, 1-165 weeks). The initial histopathologic diagnosis was poorly differentiated/squamous cell cancer in 52%, insufficient malignant cells in 14%, carcinoma in 12%, and NC in 22%. Immunohistochemistry (IHC) testing revealed NUT in 100%; 93% were keratin+, 88% p63+, 89% p40+, and 72% had Ki-67 ≥50%. IHC was used to diagnose NC in 79%. Nonthoracic primaries were associated with a longer time between symptom onset and NC diagnosis (odds ratio, 3.25). Of 32 patients who started treatment before diagnosis, 78% were on agents appropriate for NC. After a diagnosis of NC, 33% participated in clinical trials. CONCLUSION: NC almost always presents as squamous/poorly differentiated non–small cell lung or head and neck cancer. Overall, 78% of patients were initially diagnosed as non-NC. Efforts to raise awareness, recognition, and rapid diagnosis of NC by both oncologists and pathologists are critical if we are to improve outcomes.
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry
Supplementary Table S2: Patients who had a NUT IHC test and underwent DNA, ctDNA, or RNA fusion testing specifically assaying for NUTM1 fusions.
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry
Supplementary Table S2: Patients who had a NUT IHC test and underwent DNA, ctDNA, or RNA fusion testing specifically assaying for NUTM1 fusions.
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry
Supplementary Figure S3: Kaplan–Meier curve of overall survival from time of diagnostic testing. Survival curve showing overall survival from the date of the positive test that led to the diagnosis of NUT carcinoma. The y-axis indicates overall survival (%) and the x-axis represents time in months since testing.
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry
Supplementary Figure S3: Kaplan–Meier curve of overall survival from time of diagnostic testing. Survival curve showing overall survival from the date of the positive test that led to the diagnosis of NUT carcinoma. The y-axis indicates overall survival (%) and the x-axis represents time in months since testing.
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry
Supplementary Figure S4: Tumor mutation burden and PD-L1 expression among cases with DNA NGS testing. (A) Box-and-whisker plot showing tumor mutation burden (B) Bar chart showing the distribution of PD-L1 expression levels, stratified by tumor proportion score and combined proportion score. Expression levels are grouped into <1%, 1–49%, and ≥50%.
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry
Supplementary Figure S4: Tumor mutation burden and PD-L1 expression among cases with DNA NGS testing. (A) Box-and-whisker plot showing tumor mutation burden (B) Bar chart showing the distribution of PD-L1 expression levels, stratified by tumor proportion score and combined proportion score. Expression levels are grouped into <1%, 1–49%, and ≥50%.
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry
Supplementary Figure S2: Histopathological diagnosis in patients with NC who only had a NUT IHC test. Donut chart displaying the distribution of diagnoses among patients diagnosed with NUT carcinoma based only on IHC. Diagnostic categories include “carcinoma”, and a single case categorized as “other” due to limited tissue.
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry
Supplementary Figure S2: Histopathological diagnosis in patients with NC who only had a NUT IHC test. Donut chart displaying the distribution of diagnoses among patients diagnosed with NUT carcinoma based only on IHC. Diagnostic categories include “carcinoma”, and a single case categorized as “other” due to limited tissue.
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry
Supplementary Table S3: Co-occurring mutations found in DNA-based NGS with clinical relevance in NUT carcinoma.
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry
Supplementary Table S3: Co-occurring mutations found in DNA-based NGS with clinical relevance in NUT carcinoma.
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry
Supplementary Figure S6: Schematic of an example gene fusion event leading to NUT carcinoma pathogenesis. Diagram illustrating the fusion of the BRD4 and NUTM1 genes following chromosomal rearrangement. The NUTM1 fusion protein drives oncogenic transcription through upregulation of target genes such as MYC, SOX2, and p63.
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry
Supplementary Figure S6: Schematic of an example gene fusion event leading to NUT carcinoma pathogenesis. Diagram illustrating the fusion of the BRD4 and NUTM1 genes following chromosomal rearrangement. The NUTM1 fusion protein drives oncogenic transcription through upregulation of target genes such as MYC, SOX2, and p63.
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry
Supplementary Figure S1: Flowchart of patient selection and cohort assignment. Flow diagram illustrating the inclusion and exclusion of patients from the NUT carcinoma registry. Boxes show the number of patients included/excluded and how patients were assigned to the various cohorts.
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry
Supplementary Figure S1: Flowchart of patient selection and cohort assignment. Flow diagram illustrating the inclusion and exclusion of patients from the NUT carcinoma registry. Boxes show the number of patients included/excluded and how patients were assigned to the various cohorts.